Scarica l'app Stockscreener
31.40
1.04%
-0.33
Pre-mercato:
31.61
0.21
+0.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
2 Biotech Stocks Set to Rebound in 2026 - The Globe and Mail
Viking Therapeutics’ Obesity Drug Candidate Gains Momentum with Phase 2 Publication - AD HOC NEWS
Assessing Viking Therapeutics (VKTX) After Recent Pullback And Ongoing Pipeline Headlines - simplywall.st
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? - Yahoo Finance
Viking Therapeutics Stock Analysis: Growth Narrative Remains Compelling - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline - Insider Monkey
The Technical Signals Behind (VKTX) That Institutions Follow - Stock Traders Daily
3 Growth Stocks to Invest $1,000 in Right Now - The Motley Fool
The Best Stocks to Invest $40 in to Start the New Year Off Right - Finviz
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - sharewise.com
Viking Therapeutics Shares Slide Amid Analyst Downgrade and Earnings Concerns - AD HOC NEWS
Viking Therapeutics (VKTX) Is Down 5.0% After Phase 2 VK2735 Data And Phase 3 Updates – Has The Bull Case Changed? - simplywall.st
Viking Therapeutics, Inc. (VKTX) stock dips while market gains: Key facts - MSN
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly - FinancialContent
Assessing Viking Therapeutics (VKTX) Valuation As Shares Rebound Over The Past Week - Yahoo Finance
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 - Finviz
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Downgraded by Zacks Research to Strong Sell - MarketBeat
Assessing Viking Therapeutics (VKTX) Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress - simplywall.st
Can Viking Therapeutics Make a Turnaround This Year? - NAI500
2 Bargain Stocks You Can Buy for Less Than $100 Right Now - The Globe and Mail
Viking Therapeutics' Price Target of $93.39 Implies 175% Upside Potential - Intellectia AI
Viking Therapeutics (VKTX) Faces Challenges, Analysts Set Price Target of $93.39, Potential Upside of 175% - Intellectia AI
1 Stock That Could Soar by 175%, According to Wall Street - Finviz
Upcoming Oppenheimer Virtual Meeting Featuring VKTX - GuruFocus
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? - AOL.com
3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 - Finviz
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - MarketBeat
Viking Therapeutics, Inc. (VKTX) Investor Outlook: A Biotech Stock with 175% Potential Upside - DirectorsTalk Interviews
Published on: 2026-01-18 12:53:17 - baoquankhu1.vn
Viking Therapeutics Stock (VKTX) Opinions on VK2735 Obesity Drug Results - Quiver Quantitative
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Volume Summary: What is AEISs valuation compared to sector2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Viking Therapeutics: A Stock at a Crossroads Amid Obesity Drug Ambitions - AD HOC NEWS
Is Viking Therapeutics (VKTX) Now Attractive After A Strong DCF Upside Signal - Yahoo Finance
Viking Therapeutics Stock Navigates a Week of High Volatility - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
The Escalator: AstraZeneca, Viking Therapeutics, VML Health and more - Medical Marketing and Media
M&A Speculation Fuels Rally in Viking Therapeutics Shares - AD HOC NEWS
Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress - simplywall.st
Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook - Finviz
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Precision Trading with Viking Therapeutics Inc. (VKTX) Risk Zones - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) Trading 8.3% HigherShould You Buy? - MarketBeat
$VKTX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals - TechStock²
SG Americas Securities LLC Acquires 81,519 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Positioning in the Competitive Obesity Drug Arena - AD HOC NEWS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):